April 15 (Bloomberg) -- Merck & Co., the second-biggest U.S. drugmaker, retained limited rights to a share of revenue from the arthritis drug Remicade after a settlement ended its dispute with partner Johnson & Johnson.
Bloomberg's Shannon Pettypiece talks about the settlement with Betty Liu on Bloomberg Television's "In the Loop." (Source: Bloomberg)
